Assay Report
Methods · Standard Curves · QC · Results
Comprehensive Enzyme-Linked ImmunoSpot (ELISpot) and multi-color FluoroSpot assay services for single-cell functional immune monitoring across preclinical drug discovery, cellular immunotherapy, vaccine development, and infectious disease research.
By capturing and enumerating actively secreted cytokines, chemokines, cytotoxic molecules, and immunoglobulins in real time at single-cell resolution down to 1 in 1,000,000 cells, our facility quantifies functional antigen-specific T-cell and B-cell responses from human, non-human primate (NHP), and rodent peripheral blood mononuclear cells (PBMCs), splenocytes, and mucosal tissues.
Specialized single-cell secretion enumeration across translational T-cell and B-cell monitoring portfolios.
| Assay Capability & Service Focus | Target Molecules & Modalities | Primary Detection Readout | Preclinical Research & Application Focus |
|---|---|---|---|
| Polyfunctional T Cell Secretion Profiling | IFN-γ, IL-2, TNF-α, Granzyme B, IL-17A, IL-10 | Dual/Triple/Quad-color Co-secretion | Polyfunctional T-cell quality, vaccine durability, adoptive cell therapy potency, and viral memory. |
| AAV Capsid & Transgene Immunogenicity | AAV2/5/8/9 capsid libraries & transgene products | IFN-γ & IL-2 spot-forming units | Pre-IND gene therapy safety assessment, pre-existing immunity screening, and capsid re-engineering. |
| T Cell Epitope Mapping & Peptide Screening | 15-mer overlapping peptide matrix pools (PepMix) | Deconvoluted epitope spot counts | High-throughput identification of immunodominant CD4+/CD8+ neoantigens and viral vaccine epitopes. |
| CAR-T & TCR-T Potency & Cytotoxicity | Granzyme B, Perforin, IFN-γ (effector-to-target [E:T] co-culture) | Cytolytic effector cell frequency | In vitro cell product release testing, antigen-specific cytotoxic killing kinetics, and target validation. |
| B Cell ELISpot (ASC & Memory B Frequency) | Total & antigen-specific IgG, IgM, IgA isotypes | Antibody-secreting cell (ASC) counts | Memory B-cell differentiation (R848 + IL-2), vaccine humoral durability, and neutralizing antibody tracking. |
Selecting the optimal immune-monitoring platform based on single-cell frequency, cellular phenotype, and mediator concentration.
| Technical Dimension | Conventional Enzymatic ELISpot | Multi-Color FluoroSpot (Mabtech) | Flow Cytometry ICS | Soluble Cytokine Multiplex |
|---|---|---|---|---|
| Primary Readout | Single-cell frequency (1 target) | Single-cell co-secretion (1–4 targets) | Intracellular protein accumulation | Total accumulated fluid concentration |
| Analytical Sensitivity (LOD) | 1 in 100,000 to 1 in 1,000,000 | 1 in 100,000 to 1 in 1,000,000 | ~1 in 1,000 to 1 in 2,000 | 0.010 – 5.0 pg/mL (Matrix dependent) |
| Living Secretory Physiology | True active secretion | True active secretion | Trapped intracellular pool | Supernatant accumulation |
| Cell Input Requirements | 100,000 – 250,000 cells/well | 100,000 – 250,000 cells/well | 1,000,000+ cells/test | Cell-free supernatant / biofluid |
| Phenotypic Surface Markers | Limited | Limited | Extensive multi-color immunophenotyping | None |
| Polyfunctional Subpopulations | Single analyte per well | Simultaneous polyfunctional index | Co-staining capability | Cumulative bulk sum |
| Throughput & Automation | High (96-well automated) | High (Automated RAWspot analysis) | Moderate (Flow acquisition) | High (96/384-well automated) |
Standardized operating procedures and automated reader deconvolution ensuring reproducible spot enumeration.
Advanced multi-channel optical algorithms eliminate spot-overlap artifacts, distinguish true biological secretion from cellular debris, and quantify Relative Spot Volumes.
Every plate incorporates negative background controls (<5 SFU/well), polyclonal positive controls (phytohemagglutinin [PHA] >500 SFU/well), and viral recall controls (CEFX pool).
Controlled-rate thawing with Benzonase nuclease, post-thaw recovery resting, and automated cell counting eliminate non-specific in vitro clumping.
Controlled thawing of cryopreserved PBMCs/splenocytes in warm medium with Benzonase, resting, and automated viability counting.
Plating 100,000–250,000 viable cells per well in pre-coated PVDF plates with synthetic peptide pools, whole proteins, or target cells.
Incubation for 18–24 hours (T cells) or 40–48 hours (B cells) at 37°C in humidified 5% CO2 incubators without physical vibration.
Cell removal, plate washing, and incubation with fluorophore-conjugated or biotinylated detection antibodies followed by substrate development.
Automated multi-channel scanning on Mabtech readers, spot filtering, background subtraction, and normalized SFU/10^6 cell data delivery.
Standardized pre-analytical cell handling protocols ensuring membrane integrity and functional responsiveness.
| Pre-Analytical Parameter | Why It Matters for Cellular Functional Assays | Intake Specification & Recommendation |
|---|---|---|
| PBMC Isolation Timing | Delayed separation of whole blood causes granulocyte contamination and blunted T-cell responses. | Isolate PBMCs via density gradient centrifugation (Ficoll-Paque) within 8 hours of blood collection. |
| Cryopreservation Medium | Suboptimal freezing rates promote ice crystal formation and compromise membrane integrity. | Resuspend in pre-chilled freezing medium (90% FBS + 10% DMSO or CryoStor CS10); freeze at -1°C/min. |
| Post-Thaw Cell Viability | Dying cells release DNA and non-specific proteases, increasing background and suppressing antigen-specific activation. | Cell viability must exceed 80%; include a 1–2 hour recovery resting phase at 37°C prior to plating. |
| Input Cell Quantity | Accurate frequency calculation requires standardized cell seeding densities across duplicate/triplicate wells. | Provide minimum 5–10 × 10^6 cryopreserved viable cells per donor/sample to support complete assay matrices. |
| Stimulus Solubilization | Residual DMSO concentrations >0.5% in culture media induce non-specific cytotoxicity and spot inhibition. | Reconstitute peptide pools in sterile DMSO/PBS; ensure final in-well DMSO concentration is strictly <0.25% v/v. |
Applying single-cell functional secretion enumeration across cellular immunotherapy, vaccine development, and gene therapy.
Quantify long-lived memory T-cell frequencies and polyfunctional secretor profiles in mRNA, recombinant protein, and viral-vectored vaccine studies.
Evaluate in vitro antigen-specific cytolytic activity and cytokine release (CAR-T Potency ELISpot) upon tumor target co-culture.
Screen pre-existing and treatment-emergent T-cell responses against viral delivery capsids (AAV Capsid Immunogenicity).
High-throughput screening of synthetic overlapping peptide libraries (Epitope Mapping ELISpot) to identify clinical candidate targets.
Enumerate total and antigen-specific IgG/IgA/IgM antibody-secreting cells (B Cell ELISpot) to assess humoral defense.
Monitor cellular immune memory against chronic and emerging pathogens (SARS-CoV-2, CMV, EBV, Influenza, HIV) using standardized CEFX recall pools.
Standardized bioanalytical documentation, annotated spot images, and senior immunologist consultation.
Key peer-reviewed publications establishing single-cell secretion capture principles, multi-color deconvolution, and translational utility.
Study Design Takeaway: Seminal publication establishing the physical and immunological principles of solid-phase pericellular capture for single-cell secretion enumeration.
Study Design Takeaway: Validates multi-color FluoroSpot for simultaneously resolving distinct cytokine co-secretion patterns at single-cell resolution without cellular cross-talk.
Study Design Takeaway: Demonstrates that T-cell polyfunctionality (simultaneous IFN-γ, IL-2, and TNF-α secretion) correlates directly with vaccine protection and long-term immune memory.
Study Design Takeaway: Establishes standardized guidelines for PBMC cryopreservation, counting, and background subtraction in antigen-specific T-cell monitoring.
Addressing common project planning, cell handling, and assay selection inquiries.
No. ELISpot and FluoroSpot require viable, living cells (such as PBMCs, splenocytes, or purified T/B cells) because the assay captures molecules actively secreted during an ex vivo incubation period. For soluble cytokine measurement in serum or plasma, explore our Simoa Assays or MSD Platform.
ELISpot uses an enzymatic substrate reaction to produce colored precipitates, measuring one target analyte per well. FluoroSpot uses distinct fluorophore-conjugated detection reagents and multi-channel LED imaging, enabling simultaneous measurement and co-secretion profiling of up to 4 targets (e.g., IFN-γ, IL-2, TNF-α, Granzyme B) in the same microplate well.
ELISpot/FluoroSpot is 100- to 1,000-fold more sensitive than ICS, detecting rare antigen-specific secretors at frequencies as low as 1 in 1,000,000 cells without requiring toxic protein transport inhibitors. Flow cytometry is preferred when multi-parameter cell surface immunophenotyping is the primary endpoint.
Standard protocols require 100,000 to 250,000 viable cells per well. Including background negative controls, positive controls, and duplicate/triplicate wells, we typically recommend providing 5–10 × 10^6 cryopreserved viable PBMCs per donor/sample.
Every analytical run incorporates negative control wells (unstimulated cells / vehicle <5 SFU/well), positive control wells (polyclonal stimulators PHA or anti-CD3/CD28 >500 SFU/well), and viral recall controls (CEFX peptide pool) to verify cell viability, baseline responsiveness, and assay specificity.
No. All bioanalysis services provided by Creative Proteomics are strictly for Research Use Only (RUO). They are intended for preclinical drug discovery, animal disease models, translational research cohorts, and in vitro cellular characterization, and are not intended for clinical diagnostic or patient management procedures.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×